<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230526058300N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-12-30</date_registration>
      <primary_sponsor>Karaj University of Medical Sciences</primary_sponsor>
      <public_title>Investigation of beta-blockers in preventing the exacerbation of retinopathy of prematurity</public_title>
      <acronym></acronym>
      <scientific_title>Investigation of the oral (propranolol) and topical beta-blocker (Timolol eye drop) drugs in preventing the exacerbation of retinopathy of prematurity of stage 2 and above in premature neonates</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>75</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73980</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: In this study, random allocation for placement in
Each group will receive the intervention at the standard time using the block balance permuted randomization technique
. According to these blocks considered in this study, there will be six blocks. using software
STATA will generate a chain of random numbers from 1 to 6 until the desired sample size is reached. Given that the total number of states for
Receiving medicine in blocks of 6 is 6 if the number produced is more than 6, regardless of the next number.
will be produced.Preparation of random allocation sequences of drug groups and placing them in sealed envelopes
(confidential) and numbering with a 5-digit serial number by a third party who is not involved in the design of the study
All envelopes will have a 5-digit serial number that will be opened immediately after the patients enter the study.
And the patients will be divided into three groups, Blinding description: Participating parents and participants do not know in which group
are located. Eye examinations done  by only one ophthalmologist.
The doctor will take care and the ophthalmologist will not inform which group the infant is in.</study_design>
      <phase>2</phase>
      <hc_freetext>Retinopathy of prematurity.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: they receive oral propranolol 0.5 dose/kg/mg every 8 hours in addition to the standard treatment. We dissolve the propranolol tablet in the form of powder in 5% dextrose and give it to the baby after eating milk. Intervention 2: Intervention group: Timolol eye drops 0.5 drops twice a day. Intervention 3: Control group: Receiving the usual treatment for ROP means patient follow-up until complete recovery and regression of ROP or the need for intraocular injection of Avastin, surgery, laser therapy.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Hani Milani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Beheshti</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3198764653</zip>
        <telephone>+98 26 3226 6851</telephone>
        <email>hanimilani@gamil.com</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Hani Milani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Beheshti</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3198764653</zip>
        <telephone>+98 26 3226 6851</telephone>
        <email>hanimilani@gamil.com</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Gestational age  less than 34 weeks
Premature infants between 26 weeks and 34 weeks, who underwent ophthalmic  examination from the fourth to the twelfth week of birth and it was determined that they have stage 2 ROP and above.</inclusion_criteria>
      <agemin>189 days</agemin>
      <agemax>224 days</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Infants with congenital or acquired cardiac anomalies
ROP stage 1
Unstable hemodynamic</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H35.13</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Retinopathy of prematurity, stage 2</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: they receive oral propranolol 0.5 dose/kg/mg every 8 hours in addition to the standard treatment. We dissolve the propranolol tablet in the form of powder in 5% dextrose and give it to the baby after eating milk.</i_keyword>
      <i_keyword>Intervention group: Timolol eye drops 0.5 drops twice a day</i_keyword>
      <i_keyword>Control group: Receiving the usual treatment for ROP means patient follow-up until complete recovery and regression of ROP or the need for intraocular injection of Avastin, surgery, laser therapy</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Determining the progression rate of retinopathy of prematurity 3 stage in babies with retinopathy 2 stage. Timepoint: weekly examination by ophthalmologist until discharge. Method of measurement: Retcam imaging system II.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The rate of complete recovery of retinopathy of prematurity in infants with stage 2 retinopathy. Timepoint: Weekly examination by Ophthalmologist. Method of measurement: Retcam imaging system II.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Karaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-12-02</approval_date>
        <contact_name>Ethics committee of Alborz university of medical Sceiences</contact_name>
        <contact_address>45 metri Golshahr Karaj Alborz Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
